ARTICLE | Clinical News
Anetumab ravtansine: Phase II started
February 1, 2016 8:00 AM UTC
Bayer began an open-label, international Phase II trial to compare 6.5 mg/kg IV anetumab ravtansine every 3 weeks vs. IV vinorelbine once weekly in about 183 patients. The start triggered an undisclos...